Printer Friendly

CELLEX BIOSCIENCES, INC. ENTERS INTO DISTRIBUTION AGREEMENT WITH TOSOH CORPORATION OF JAPAN

 MINNEAPOLIS, June 24 /PRNewswire/ -- Cellex Biosciences, Inc. (NASDAQ: CLXX) announced today that it has entered into a distribution agreement with Tosoh Corporation, a diversified international chemical products company with headquarters in Tokyo. Tosoh will market the newly acquired Verax products in Japan for Cellex Biosciences. The Verax technology, which was acquired by Cellex Biosciences in May 1993, utilizes a fluidized bed cell culture technology that has proven to be effective for the growth of certain types of cells including monoclonal antibodies and recombinant proteins. The agreement was assumed by Cellex Biosciences upon acquisition of the product line and is in force until Dec. 31, 1993, at which time the agreement is expected to be extended based on mutually agreeable minimum order purchases by Tosoh.
 Richard E. Sakowicz, Cellex Biosciences, Inc. president and chief operating officer, said, "We are very pleased to have Tosoh as our distribution partner in Japan. This agreement will bring us one step closer to strengthening our sales in Japan. The Scientific Instruments Division of Tosoh Corporation will initiate sales activities with the focused effort in placing the benchtop System One and System 20 into key Japanese pharmaceutical companies. The commercial achievements of Tosoh are internationally recognized, and we look forward to a further enhancement of our growing worldwide capability to service our customers."
 Cellex Biosciences, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide.
 -0- 6/24/93
 /CONTACT: Yvonne L. Marschner-Bova, director, investor relations, Cellex Biosciences, Inc., 313-871-7350/
 (CLXX)


CO: Cellex Biosciences, Inc.; Tosoh Corporation ST: Minnesota IN: MTC SU: LIC

JG -- DE009 -- 5226 06/24/93 10:19 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 24, 1993
Words:281
Previous Article:SCHERER ANNOUNCES AGREEMENT WITH GLAXO
Next Article:SHARPE TO HEAD WACKENHUT'S EUROPEAN/CANADIAN OPERATIONS
Topics:


Related Articles
CELLEX BIOSCIENCES, INC. RECEIVES $500,000 GOVERNMENT GRANT FOR FURTHER DEVELOPMENT OF ITS OXYCELL BIOREACTOR
ALAMAR BIOSCIENCES SIGNS DISTRIBUTION AGREEMENT FOR JAPAN
CELLEX BIOSCIENCES, INC. DEFENDS CLAIM OF TRADEMARK INFRINGEMENT
CELLEX BIOSCIENCES APPOINTS VICE PRESIDENT, SALES AND MARKETING
CELLEX BIOSCIENCES RECEIVES U.S. PATENT ON CELL CULTURE APPARATUS
CELLEX BIOSCIENCES ANNOUNCES LSL BIOLAFITTE ORDER FROM GENENCOR INTERNATIONAL INC.
CELLEX BIOSCIENCES, INC. NEWS NOW AVAILABLE VIA FAX
CELLEX BIOSCIENCES ANNOUNCES 'CE' MARK CERTIFICATION
CELLEX BIOSCIENCES SUPPLIED PERFUSION EQUIPMENT FOR 1ST RECOMMENDED INJECTABLE PRODUCT PRODUCED IN HOLLOW FIBER
CELLEX BIOSCIENCES Announces Termination of Merger Agreement With UNISYN Technologies, Discussions Continuing

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters